Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment

Journal of Diabetes and its Complications

Volumn 31, Issue 1, 2017, Pages 162-168

  Zobel, Emilie Hein ^a   von Scholten, Bernt Johan ^a   Lindhardt, Morten ^a   Persson, Frederik ^a   Hansen, Tine Willum ^a   Rossing, Peter ^a,b,c  

^a STENO DIABETES CENTER   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

Diabetic nephropathy; Glomerular filtration rate; GLP 1; Liraglutide; Type 2 diabetes

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; EDETATE CHROMIUM CR 51; HEMOGLOBIN A1C; LIRAGLUTIDE; METFORMIN; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); DIABETIC PATIENT; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOME ASSESSMENT; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RISK FACTOR; SECONDARY ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT RESPONSE; URINALYSIS; URINARY EXCRETION; AGED; AGONISTS; BLOOD; CLINICAL TRIAL; COMPLICATION; DENMARK; DIABETIC NEPHROPATHY; DISEASE PREDISPOSITION; DRUG EFFECTS; DRUG RESISTANCE; GLOMERULUS FILTRATION RATE; KIDNEY; KIDNEY FAILURE; METABOLISM; PATHOPHYSIOLOGY; REPRODUCIBILITY;

AGED; BIOMARKERS; DENMARK; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE; FEMALE; GLOMERULAR FILTRATION RATE; GLUCAGON-LIKE PEPTIDE 1; GLYCATED HEMOGLOBIN A; HUMANS; HYPOGLYCEMIC AGENTS; KIDNEY; LIRAGLUTIDE; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; REPRODUCIBILITY OF RESULTS; RISK FACTORS;

EID: 85005952250     PISSN: 10568727     EISSN: 1873460X     Source Type: Journal    
DOI: 10.1016/j.jdiacomp.2016.09.016     Document Type: Article

References (27)

1. Afshinnia, F., Wilt, T.J., Duval, S., Esmaeili, A., Ibrahim, H.N., Weight loss and proteinuria: systematic review of clinical trials and comparative cohorts. Nephrology, Dialysis, Transplantation 25:4 (2010), 1173–1183.
2. Apperloo, A.J., de Zeeuw, D., de Jong, P.E., A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney International 51:3 (1997), 793–797.
3. American Diabetes Association. Diabetes Care, 39(Suppl. 1), 2016, 72.
4. Bloomgarden, Z.T., Dodis, R., Viscoli, C.M., Holmboe, E.S., Inzucchi, S.E., Lower baseline glycemia reduces apparent oral agent glucose-lowering efficacy: a meta-regression analysis. Diabetes Care 29:9 (2006), 2137–2139.
5. Brochner-Mortensen, J., A simple method for the determination of glomerular filtration rate. Scandinavian Journal of Clinical and Laboratory Investigation 30:3 (1972), 271–274.
6. Cherney, D.Z., Perkins, B.A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., von Eynatten, M., Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129:5 (2014), 587–597.
7. Davies, M.J., Bain, S.C., Atkin, S.L., Rossing, P., Scott, D., Shamkhalova, M.S., Umpierrez, G.E., Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): a randomized clinical trial. Diabetes Care 39:2 (2016), 222–230.
8. Fonseca, V.A., Devries, J.H., Henry, R.R., Donsmark, M., Thomsen, H.F., Plutzky, J., Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. Journal of Diabetes and its Complications 28:3 (2014), 399–405.
9. Heerspink, H.J., de Zeeuw, D., The kidney in type 2 diabetes therapy. The Review of Diabetic Studies 8:3 (2011), 392–402.
10. Holtkamp, F.A., de Zeeuw, D., Thomas, M.C., Cooper, M.E., de Graeff, P.A., Hillege, H.J., Heerspink, H.J., An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney International 80:3 (2011), 282–287.
11. Jones, A.G., McDonald, T.J., Shields, B.M., Hill, A.V., Hyde, C.J., Knight, B.A., Hattersley, A.T., Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39:2 (2016), 250–257.
12. Kim, D., MacConell, L., Zhuang, D., Kothare, P.A., Trautmann, M., Fineman, M., Taylor, K., Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. Diabetes Care 30:6 (2007), 1487–1493.
13. Lewis, E.J., Hunsicker, L.G., Bain, R.P., Rohde, R.D., The effect of angiotensin-converting enzyme-inhibition on diabetic nephropathy. New England Journal of Medicine 329:20 (1993), 1456–1462.
14. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Buse, J.B., Liraglutide and cardiovascular outcomes in type 2 diabetes. The New England Journal of Medicine, 2016.
15. Nauck, M., Frid, A., Hermansen, K., Shah, N.S., Tankova, T., Mitha, I.H., Matthews, D.R., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 32:1 (2009), 84–90.
16. Patel, A., Group, A.C., MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Williams, B., Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:9590 (2007), 829–840.
17. Rossing, P., Hommel, E., Smidt, U.M., Parving, H.H., Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37:5 (1994), 511–516.
18. Schievink, B., Mol, P.G., Lambers Heerspink, H.J., Surrogate endpoints in clinical trials of chronic kidney disease progression: moving from single to multiple risk marker response scores. Current Opinion in Nephrology and Hypertension 24:6 (2015), 492–497.
19. Skov, J., Pedersen, M., Holst, J.J., Madsen, B., Goetze, J.P., Rittig, S., Christiansen, J.S., Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. Diabetes, Obesity & Metabolism 18:6 (2016), 581–589.
20. Tonneijck, L., Smits, M.M., Muskiet, M.H., Hoekstra, T., Kramer, M.H., Danser, A.H., van Raalte, D.H., Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial. Diabetologia 59:7 (2016), 1412–1421.
21. UKPDS group, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) group. Lancet, 352(9131), 1998, 854–865.
22. UKPDS group, Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study group. BMJ, 317(7160), 1998, 703–713.
23. Vilsboll, T., Christensen, M., Junker, A.E., Knop, F.K., Gluud, L.L., Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ, 344, 2012, d7771.
24. von Scholten, B.J., Hansen, T.W., Goetze, J.P., Persson, F., Rossing, P., Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. Journal of Diabetes and its Complications 29:5 (2015), 670–674.
25. von Scholten, B.J., Lajer, M., Goetze, J.P., Persson, F., Rossing, P., Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. Diabetic Medicine 32:3 (2015), 343–352.
26. von Scholten, B.J., Orsted, D.D., Svendsen, A.L., Persson, F., Rossing, P., The influence of pharmaceutically induced weight changes on estimates of renal function: a patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication. Journal of Diabetes and its Complications 29:8 (2015), 1146–1151.
27. Wanner, C., Inzucchi, S.E., Lachin, J.M., Fitchett, D., von Eynatten, M., Mattheus, M., Zinman, B., Empagliflozin and progression of kidney disease in type 2 diabetes. The New England Journal of Medicine, 2016.